阅读说明：本技术 一种组合物及其制备方法与应用 (Composition and preparation method and application thereof ) 是由 杨鹏 刘锐 谭健兵 李珍 邹辉 于 2021-09-30 设计创作，主要内容包括：本发明公开了一种组合物及其制备方法与应用。所述组合物的制备原料包括：β-葡聚糖5-20份、甘露聚糖5-30份、酵母菌多肽类8-15份和透明质酸钠1-20份。本发明制备的组合物,通过上述制备原料以特定的协同作用修复受损皮肤和治疗口腔疾病；在治疗敏感肌、晒伤肌肤、痤疮、痘痘肌、糖尿病足和血管神经性溃疡、浅表创面及口腔溃疡、牙菌斑和牙周炎等方面都具有明显的疗效。(The invention discloses a composition, a preparation method and application thereof. The preparation raw materials of the composition comprise: 5-20 parts of beta-glucan, 5-30 parts of mannan, 8-15 parts of saccharomycete polypeptide and 1-20 parts of sodium hyaluronate. The composition prepared by the invention can repair damaged skin and treat oral diseases by the prepared raw materials with specific synergistic effect; has obvious curative effect on sensitive muscle, sunburn skin, acne skin, diabetic foot, angioneurotic ulcer, superficial wound, oral ulcer, dental plaque, periodontitis and the like.)

1. A composition, characterized in that it is prepared from the following raw materials: 5-20 parts of beta-glucan, 5-30 parts of mannan, 8-15 parts of saccharomycete polypeptide and 1-20 parts of sodium hyaluronate.

2. The composition of claim 1, wherein the composition is prepared from a starting material comprising: 5-10 parts of beta-glucan, 15-20 parts of mannan, 8-12 parts of saccharomycete polypeptide and 3-8 parts of sodium hyaluronate.

3. The composition according to claim 2, wherein the composition comprises the following raw materials in parts by mass: 10 parts of beta-glucan, 20 parts of mannan, 10 parts of saccharomycete polypeptide and 5 parts of sodium hyaluronate.

4. The composition of claim 1, wherein the raw materials for preparing the composition further comprise: glycerin, carbomer, sodium methyl hydroxybenzoate and/or triethanolamine.

5. The composition according to claim 4, further comprising the following raw materials in parts by mass: 5-15 parts of carbomer, 20-40 parts of glycerol, 1-5 parts of sodium methyl hydroxybenzoate and 5-20 parts of triethanolamine.

6. A process for the preparation of a composition according to any one of claims 1 to 5, comprising the steps of: mixing the preparation raw materials of the composition to obtain the composition.

7. Use of a composition according to any one of claims 1 to 5 in the manufacture of a medicament for promoting healing of a skin wound.

8. Use of a composition according to any one of claims 1-5 for the manufacture of a medicament for the treatment of scald.

9. Use of a composition according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of an oral disease.

10. Use according to claim 9, wherein the oral diseases are oral ulcers, periodontitis and dental caries.

Technical Field

The invention relates to the field of medicines, and particularly relates to a composition, and a preparation method and application thereof.

Background

In modern society, due to the reasons of fast pace of life, large pressure on life and work, irregular work and rest time and the like, a large number of skin problems such as skin allergy, sensitive muscle, acne, eczema, dermatitis and the like occur, in addition, the living standard of people is also increasing day by day, and higher requirements are provided for series of problems caused by skin injury. In the existing solution, most of medicines are hormones, and certain side effects and drug resistance exist; skin care products such as cosmetics are also used, but mainly moisturize skin, and have a poor healing effect on damaged skin or a long healing time. Oral diseases comprise damaged oral mucosa such as oral ulcer, tooth decay, oral erosion, gingival bleeding, periodontitis, gingivitis and the like, the oral diseases can seriously affect the life quality of people, and even bring other complications such as diseases of kidney, coronary artery or liver and the like, and the increasingly developed oral market urgently needs oral products with outstanding effects and no side effects.

The existing market lacks a medicament capable of treating skin diseases and oral diseases simultaneously, so that the application scheme provides a composition with outstanding effect and no side effect, can effectively promote skin wound healing, and has a certain treatment effect on the oral diseases.

Disclosure of Invention

The present invention is directed to solving at least one of the problems of the prior art. Therefore, the composition provided by the invention can effectively promote the healing of skin wounds and has a certain treatment effect on oral diseases.

The invention also provides a preparation method of the composition.

The invention also provides application of the composition.

The composition according to an embodiment of the first aspect of the present invention, the composition being prepared from raw materials comprising: 5-20 parts of beta-glucan, 5-30 parts of mannan, 8-15 parts of saccharomycete polypeptide and 1-20 parts of sodium hyaluronate.

According to some embodiments of the invention, the composition comprises the following raw materials in parts by mass: 5-10 parts of beta-glucan, 15-20 parts of mannan, 8-12 parts of yeast polypeptide and 3-8 parts of sodium hyaluronate.

According to some embodiments of the invention, the composition comprises the following raw materials in parts by mass: 8-12 parts of beta-glucan, 18-22 parts of mannan, 8-12 parts of yeast polypeptide and 3-6 parts of sodium hyaluronate.

According to some embodiments of the invention, the composition comprises the following raw materials in parts by mass: 10 parts of beta-glucan, 20 parts of mannan, 10 parts of saccharomycete polypeptide and 5 parts of sodium hyaluronate.

According to some embodiments of the invention, the starting materials for the preparation of the composition further comprise: glycerin, carbomer, sodium methyl hydroxybenzoate and/or triethanolamine.

According to some embodiments of the invention, the composition further comprises the following raw materials in parts by mass: 5-15 parts of carbomer, 20-40 parts of glycerol, 1-5 parts of sodium methyl hydroxybenzoate and 5-20 parts of triethanolamine.

According to some embodiments of the invention, the composition further comprises the following raw materials in parts by mass: 30 parts of glycerol, 10 parts of carbomer, 1 part of sodium hydroxybenzoate and 15 parts of triethanolamine. Triethanolamine and carbomer form a stable emulsifying structure to prevent skin from forming physical isolation with external bacteria, sodium methyl hydroxybenzoate is used as bacteriostatic agent and antiseptic, and glycerol is used as humectant.

According to some embodiments of the invention, the carbomer is selected from one of the following: carbomer 940, carbomer 941, carbomer 934, preferably, carbomer 941.

According to some embodiments of the invention, the composition is in a dosage form of one of a paste, a foam, an aerosol, a powder, a solution, an emulsion, and a slurry.

According to some embodiments of the invention, the beta-glucan is derived from yeast cell wall extract and has a molecular weight below 500000D, preferably the beta-glucan has a molecular weight below 200000D.

According to some embodiments of the invention, the mannan is derived from yeast cell wall extract and has a molecular weight below 500000D, preferably the beta-glucan has a molecular weight below 200000D.

According to a second aspect of the present invention, there is provided a method of preparing the above composition, comprising the steps of: mixing beta-dextran, mannan, yeast polypeptide, sodium hyaluronate, carbomer, glycerol, sodium methyl hydroxybenzoate and triethanolamine.

According to a third aspect of the present invention, the use is for the preparation of a medicament for promoting healing of a skin wound.

According to some embodiments of the invention, the use is the use of the above composition for the preparation of a medicament for the treatment of scald.

According to some embodiments of the invention, the use is the use of a composition as described above for the preparation of a medicament for skin repair.

According to some embodiments of the invention, the use is the use of the above composition for the preparation of a skin care medicament.

According to some embodiments of the invention, the use is in the manufacture of a medicament for the treatment of an oral disease.

According to some embodiments of the invention, the oral disease is dental ulcer, periodontitis and caries.

A medicine for promoting skin wound healing comprises the composition.

According to some embodiments of the invention, the medicament for promoting healing of a skin wound further comprises one or more of a pharmaceutically and/or dermatologically acceptable humectant, emollient, surfactant, rheology modifier, skin penetration enhancer, flavoring agent, water-soluble film-forming polymer, preservative, pH adjuster, or fragrance.

The invention has the beneficial effects that: the composition prepared by the invention can repair damaged skin and treat oral diseases through specific synergistic effect by using beta-glucan, mannan, saccharomycete polypeptide, sodium hyaluronate, carbomer, glycerin, sodium hydroxybenzoate and triethanolamine. The yeast beta-glucan is used for inducing the expression of TNF-alpha in wound macrophages, mannan has the functions of resisting viruses, promoting wound healing and resisting oxidation, the beta-glucan and the mannan generate obvious synergistic interaction, the remarkable skin care and repair effects can be achieved, the generation of dental plaque can be effectively inhibited, the growth of streptococcus mutans, candida oralis and porphyromonas can be effectively inhibited, and the remarkable curative effects on oral diseases such as the formation of decayed teeth, periodontitis, oral ulcer and the like are achieved. The beta-glucan and the mannan adopted by the scheme of the invention belong to edible grade, are derived from yeast, are natural and safe, and the composition prepared by the scheme of the invention has obvious treatment effects on chronic ulcer wounds such as sensitive muscles, sunburn skin, acne, pox muscles, diabetic feet, angioneurotic ulcer and the like, superficial wounds, oral ulcer, periodontitis, gingival inflammation and decayed tooth prevention.

Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.

Drawings

The invention is further described with reference to the following figures and examples, in which:

FIG. 1 is a graph showing the effect of the composition prepared in example 1 on the cell scratch test in the test example of the present invention;

FIG. 2 is a graph showing the effect of the composition prepared in comparative example 1 in the test examples of the present invention on the cell scratch test;

FIG. 3 is a graph showing the effect of the composition prepared in comparative example 2 on the cell scratch test in the test examples of the present invention;

FIG. 4 is a graph showing the effect of the composition prepared in comparative example 3 in the test examples of the present invention on the cell scratch test;

FIG. 5 is a graph showing the results of treatment of superficial scratch by the composition prepared in example 1 of the test example of the present invention;

FIG. 6 is a graph showing the results of treatment of scald with the composition prepared in example 1 in the test example of the present invention;

fig. 7 is a graph showing the effect of the composition prepared in example 1 of the test example of the present invention on plaque staining on teeth before and after brushing.

Detailed Description

The concept and technical effects of the present invention will be clearly and completely described below in conjunction with the embodiments to fully understand the objects, features and effects of the present invention. It is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments, and those skilled in the art can obtain other embodiments without inventive effort based on the embodiments of the present invention, and all embodiments are within the protection scope of the present invention. The test methods used in the examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are commercially available reagents and materials unless otherwise specified.

Example 1

An embodiment of the composition of the present invention comprises the following components, by weight: 1% of beta-glucan, 2% of mannan, 1% of saccharomycete polypeptide, 0.5% of sodium hyaluronate, 9411% of carbomer, 3% of glycerol, 0.1% of sodium methyl hydroxybenzoate, 1.5% of triethanolamine and the balance of water.

The preparation method of the composition in this example is as follows:

(1) adding appropriate amount of purified water into a stirring tank, adding 1% carbomer 941, stirring at 80 deg.C for dissolving, maintaining at 80 deg.C for 30min, starting cooling water, and cooling;

(2) adding 1% of beta-glucan, 2% of mannan, 1% of saccharomycete polypeptide, 0.5% of sodium hyaluronate, 3% of glycerol, 0.1% of sodium methyl hydroxybenzoate and 1.5% of triethanolamine and the balance of water into a stirring tank to dissolve all the components;

(3) and (3) mixing and stirring the mixture obtained in the steps (1) and (2) for 10 minutes.

Example 2

An example of the composition prepared by the present invention contains the following components by weight: 1% of beta-glucan, 1% of mannan, 1% of saccharomycete polypeptide, 0.5% of sodium hyaluronate, 9411% of carbomer, 3% of glycerol, 0.1% of sodium methyl hydroxybenzoate, 1.5% of triethanolamine and the balance of water.

The composition in this example was prepared in the same manner as in example 1.

Example 3

An example of the composition prepared by the present invention contains the following components by weight: 2% of beta-glucan, 1% of mannan, 1% of saccharomycete polypeptide, 0.5% of sodium hyaluronate, 9411% of carbomer, 3% of glycerol, 0.1% of sodium methyl hydroxybenzoate, 1.5% of triethanolamine and the balance of water.

The composition in this example was prepared in the same manner as in example 1.

Example 4

An embodiment of the composition of the present invention comprises the following components, by weight: 1% of beta-glucan, 1% of mannan, 1% of saccharomycete polypeptide, 0.2% of sodium hyaluronate, 9411% of carbomer, 2% of glycerol, 0.1% of sodium methyl hydroxybenzoate, 1.5% of triethanolamine and the balance of water.

The composition in this example was prepared in the same manner as in example 1.

Example 5

An embodiment of the composition of the present invention comprises the following components, by weight: 1% of beta-glucan, 1% of mannan, 0.5% of saccharomycete polypeptide, 2% of sodium hyaluronate, 9411% of carbomer, 1% of glycerol, 0.1% of sodium methyl hydroxybenzoate, 1.5% of triethanolamine and the balance of water.

The composition in this example was prepared in the same manner as in example 1.

Comparative example 1

A comparative example of a composition of the invention, which differs from example 1 only in the removal of β -glucan from the starting material of the preparation. The sources of the remaining components and the method of making the composition were the same as in example 1.

Comparative example 2

A comparative example of the composition of the invention, which differs from example 1 only in the removal of mannan from the starting material of the preparation. The sources of the remaining components and the method of making the composition were the same as in example 1.

Comparative example 3

A comparative example of the composition of the invention, which differs from example 1 only in the removal of β -glucan and mannan from the starting material of the preparation. The sources of the remaining components and the method of making the composition were the same as in example 1.

Test example

1. Skin repair promoting Activity test

(1) Promotion of Human Skin Fibroblast (HSF) proliferation (MTT assay)

Collecting cells in logarithmic growth phase, digesting, and preparing into 1 × 10 concentration DMEM medium containing 10% fetal calf serum and 1% double antibody⁵The cell suspension was inoculated in a 96-well plate at 150. mu.L/well, 37 ℃ and 5% CO₂After 24h of incubation in the incubator, the medium was changed to DMEM containing 100 μ g/mL of the experimental group, negative control group (containing equal amount of cell suspension) and blank control group (containing equal amount of 1% double antibody). The test groups were added to example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3, respectively, and the culture was continued by adding 1% double-resistant DMEM medium to each well of the negative control group and the blank control group. Each group is provided with at least 3 multiple wells, after shaking uniformly, culturing for 24h and 48h, removing culture medium by aspiration, washing with PBS, adding 20 μ LMTT solution (5mg/mL) per well, at 37 deg.C and 5% CO₂Culturing for 4h, removing supernatant, adding DMSO 150 μ L into each well, and shaking for 10min to dissolve the crystals. The absorbance of each well was measured at 490nm using a microplate reader. The experiment was simultaneously performed for the blank group containing no sample solution, and the proliferation survival rate was calculated according to the calculation formula shown below, and the experiment was repeated 3 times.

Proliferation survival (%) × (experimental absorbance-blank absorbance)/(negative control absorbance-blank absorbance) × 100%.

TABLE 1

Note: compared with the negative control group, the test results show that,^*P＜0.05，^**P＜0.01，^▲P＞0.05

the results of the experimental groups on HSF proliferation survival rate at different action times are shown in table 1, and it can be seen from the table that compared with the negative control group, the 24 and 48h experimental groups have proliferation promoting effect (p is less than 0.05) on HSF, and the effect after 48h administration is better. The proliferation promoting effect of the 24h comparative example 3 is not increased (p is more than 0.05), the proliferation promoting effect of the 24h and 48h example 1 on HSF is obviously larger than that of the comparative examples 1, 2 and 3, the proliferation promoting effect of the example 1 is the best, and the proliferation promoting effect of the three examples has more obvious advantages compared with the proliferation promoting effects of the comparative examples 1 (lack of yeast beta-glucan), the comparative examples 2 (lack of yeast mannan) and the comparative examples 3 (lack of yeast beta-glucan and yeast mannan). Meanwhile, when the weight ratio of the yeast beta-glucan to the yeast mannan is 1:2, the yeast beta-glucan and the yeast mannan can generate a good proliferation promoting effect on human skin fibroblasts.

(2) Promoting human skin fibroblast migration (cell scratch test)

Collecting cells in logarithmic growth phase, digesting, and preparing into 1 × 10 concentration DMEM medium containing 15% fetal calf serum and 1% double antibody⁵The cell suspension was inoculated in 6-well plates at 2 mL/well, 37 ℃ and 5% CO₂After 24h incubation in the incubator, the wells were each scratched straight with 1mL pipette tip gently at the center of each well, washed with PBS, and 2mL of DMEM medium containing 100. mu.g/mL of the composition (prepared in example 1, control 2, and control 3), 15% fetal bovine serum, and 1% double antibody was added, 2mL of DMEM medium containing 15% fetal bovine serum and 1% double antibody was added to the blank, each of 3 duplicate wells, and after further incubation for 24h, observed under an inverted microscope and photographed.

The results of the cell scratch test are shown in fig. 1 to 4, and it can be seen from the graphs that the cell migration speed is fastest by adding the composition prepared in example 1, indicating that the healing effect on the wounded skin is most significant.

2. Free radical scavenging Effect test

1. Experimental materials: the compositions prepared in example 1 and comparative examples 1 to 3 were dissolved in water to prepare a 5% aqueous solution as a sample to be measured.

2. The experimental process comprises the following steps:

(1) hydroxyl radical scavenging experiments: adding 0.5ml of 0.75mmol/L o-diazaphenanthrene absolute ethanol solution into a stoppered test tube, respectively adding 2ml of 0.2mol/L phosphate buffer solution (pH 7.4) and 1ml of sample to be tested, mixing well, adding 0.5ml of 0.75mmol/L FeSO₄·7H₂O solution, mixing again, adding 0.5ml H with concentration of 0.01% (v/v)₂O₂After reacting in a constant-temperature water bath at 37 ℃ for 60min, respectively measuring the absorbance value of each group of mixture solution at 536nm, recording as Ax, measuring the absorbance value with distilled water as a blank group, recording as Ab, and replacing H with distilled water₂O₂As lesion group, absorbance values were determined, An, according to the formula: the hydroxyl radical scavenging rate was calculated as (Ax-An)/(Ab-An) × 100%.

(2) DPPH free radical scavenging experiments: taking 3ml of DPPH absolute ethanol solution with the concentration of 0.2mmol/L into a cuvette, adding 1ml of sample to be detected, uniformly mixing, carrying out a reaction at room temperature in a dark place for 30min, and measuring the absorbance value at the wavelength of 517nm and marking as Ax; measuring absorbance value by taking 3ml of absolute ethyl alcohol and 1ml of sample to be measured as blank control, and marking as Ab; using 3ml of DPPH absolute ethanol solution and 1ml of absolute ethanol solution as a control group, measuring the absorbance value, marking as An, according to the formula: DPPH radical clearance ═ 1- (Ax-Ab)/An ] × 100%, DPPH radical clearance was calculated.

TABLE 2 determination of radical scavenging Effect of the compositions

Group of	Hydroxyl radical scavenging rate (%)	DPPH radical scavenging ratio (%)
			Example 1	85.2±7.23	86.7±9.21
Comparative example 1	34.5±4.55	36.7±2.86
			Comparative example 2	43.6±5.37	42.9±3.57
Comparative example 3	10.4±2.89	11.6±3.16

Note: p is less than 0.05.

3. The experimental results are as follows: the DPPH free radical scavenging result is shown in Table 2, and it can be seen from the table that the composition prepared in example 1 of the present invention has hydroxyl free radical and DPPH free radical scavenging rates of over 80%, and can significantly delay skin cell aging; compared with the comparative examples 1-3, the hydroxyl radical and DPPH radical clearance rate of the components of the composition is changed to be remarkably reduced respectively, which shows that the technical effect of the scheme is realized through the synergistic effect of the beta-glucan and the mannan.

3. In vitro transdermal absorption test

Vertical modified Franz diffusion cells (20mL) and the skin of the piglet abdomen ex vivo were used. The in vitro skin is fixed between the sample cell and the receiving cell, and the horny layer faces toThe sample cell was evenly coated with the test gel and the back of the skin was in intimate contact (no air bubbles) with a receiving solution (0.9% sodium chloride injection). Effective diffusion area of about 3cm²And the receiving system is placed in a constant temperature system with the temperature of 32 +/-0.5 ℃, and is electromagnetically stirred at the rotating speed of 400 revolutions per minute. 1mL of the receiving solution was taken at 1 hour, the test was terminated, the pigskin was immediately taken out, the gel remaining in the epidermis was washed, and the receiving solution was then diluted to 10 mL. Centrifuging at high speed (10000 rpm) for 5min, collecting supernatant, and filtering to obtain intradermal residue determination solution.

And (3) calculating the content of beta-glucan and mannan in the receiving solution by adopting an HPLC differential detection method according to an external standard method by using peak areas, and calculating the skin permeation rate. The skin penetration rate is the content in the receiving liquid/the content of the sample multiplied by 100%.

TABLE 3

Test examples	Permeability of beta-glucan	Permeability of mannan
			Example 1	22％	18％
Example 4	13％	12％
			Example 5	10％	8％

The experimental results are shown in table 3, and it can be seen that the formulation of the composition according to the present invention has a significant synergistic effect.

4. Bacteriostasis test

The bacteriostatic activity of example 1 and comparative examples 1 to 3 on oral pathogens was tested, taking Porphyromonas endodontium and Streptococcus mutans as examples.

Suspending Porphyromonas pulposus in brain heart infusion broth, and culturing at 37 deg.C for 48 hr; suspending Streptococcus mutans in trypticase soy broth, and culturing at 37 deg.C for 48 h; centrifuging at 3000r/min for 10min, discarding supernatant, and collecting bacterial liquid. The experiment was divided into 10 groups, namely, physiological saline solutions of example 1, comparative examples 1 to 3 and control group, and the samples of example 1 and comparative examples 1 to 3 were prepared as aqueous solutions of equal cell concentration. Circular filter paper sheets of 6mm in diameter sterilized at 121 ℃ for 15min were soaked in 1ml each of the aqueous solutions of examples and comparative examples and physiological saline, 5 filter paper sheets for each solution, and after 5min, they were taken out and drained. Prepared porphyromonas endodontis and streptococcus mutans bacterial liquids are respectively dipped by aseptic cotton swabs, lightly and parallelly crossed and scribed on a blood agar plate in 4 directions, and the obtained product is uniformly coated. Filter paper sheets soaked with different sample solutions were placed on the surface of inoculated bacterial agar plates, respectively. Each sample was repeated 6 times for each bacterium. Each plate was incubated in an incubator at 37 ℃ for 48 hours, and the diameter of the zone of inhibition on each plate was measured with a vernier caliper.

TABLE 4

Group of	Porphyromonas pulposus (mm)	Streptococcus mutans (mm)
			Example 1	25.2±2.43*	16.4±1.26*
Comparative example 1	14.5±1.15*	7.7±1.83*
			Comparative example 2	6.6±0.67	4.9±0.93
Comparative example 3	1.4±0.59	1.6±0.16
			Control group	0.0±0.0	0.0±0.0

Note: p is less than 0.05.

As shown in Table 4, it can be seen that the inhibition of Porphyromonas pulposus and Streptococcus mutans is most significant in example 1, whereas Porphyromonas and Prevotella are considered as periodontal pathogens, and the formation of dental plaque in teeth is indicated as a cause of dental caries, and under the condition that dental plaque is severely acidified for a long time, eosinophilic microorganisms such as Streptococcus mutans are dominant, and if the formation of dental plaque is fundamentally avoided and the growth of Streptococcus mutans is inhibited, the formation of dental caries is significantly prevented. The experimental result shows that the composition prepared in example 1 has good application prospect in preparing the medicine for treating oral diseases.

5. Clinical trial

(1) Experiment for promoting healing of skin wound

60 superficial scratch patients were selected and randomly divided into observation groups and control groups, each of which was 30, and the age of the patients was between 20 and 55 years. The control group was applied with commercially available skin repair drugs, and the observation group was applied with example 12 times a day on and around the damaged skin for a total period of 10 days.

Observation indexes are as follows: comparing the treatment effect and skin function test result of two groups of patients.

The effect is shown: the damaged skin of the patient is completely healed after treatment, and no scar is left.

The method has the following advantages: the injured skin of the patient is completely healed after treatment, and scars are obviously improved.

And (4) invalidation: the damaged skin was not improved after the treatment.

As a result: the control group had significantly lower treatment effect than the observation group, the data between the groups were not statistically different (p < 0.05), and the treatment effect of the patients is shown in Table 5:

TABLE 5

Group of	Number of examples	Show effect	Is effective	Invalidation	Total effective rate
						Observation group	30	24(80％)	5(16.7％)	1(3.3％)	29(96.7％)
Control group	30	14(46.7％)	12(40％)	4(13.3％)	26(86.7％)

Note: p is less than 0.05.

As can be seen from Table 5, the observed group had better wound skin repair than the control group, and the data between groups had statistical significance (p < 0.05).

1 case of 5-year-old superficial scratched patients was selected and applied with the composition prepared in example 1 of the present embodiment as an informed consent patient, and the experimental results are shown in fig. 5, in which it can be seen that the wounds recovered to be normal after the scratched patients had been used for 3 days.

(2) Effect of smearing for scald

1 patient with scald is selected, and the composition prepared in the embodiment 1 of the application is applied to the patient with informed consent for 3 times a day so as to uniformly cover the surface skin, and the experimental result is shown in fig. 6, and it can be seen from the figure that the wound of the patient with scald is healed and the surface skin is basically normal after the patient with scald is used for 10 days.

(3) Experiment for inhibiting formation of dental plaque

20 subjects of 20 to 55 years old were selected and the plaque staining effect on teeth was compared by a plaque disclosing solution (Wuhan ya Yak's Biotech Co., Ltd., product name: Sedi) before and after brushing teeth with the composition prepared in example 1. The experimental result is shown in fig. 7, and it can be seen from the figure that after brushing teeth for 2-3 minutes with the composition prepared in example 1 every day, the red dental plaque attached to the teeth is significantly reduced after 1 month, which indicates that the composition prepared by the scheme of the present invention can inhibit the formation of dental plaque on the tooth surface, and can effectively prevent dental caries, halitosis and oral inflammation.

The yeast beta-glucan and yeast mannan used in the examples and comparative examples of the present invention were all commercially available conventional products.

The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention. Furthermore, the embodiments of the present invention and the features of the embodiments may be combined with each other without conflict.